Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

DARTRIX

Financiado

Cerrado

DARPin Targeted Magnetic Hyperthermic Therapy for Glioblastoma

DARTRIX, ‘DARPin Targeted RX (therapy)’ is a multidisciplinary collaborative project that will develop high-affinity protein scaffolds to create a new generation of targeted therapeutics for the treatment of glioblastoma. There is... ver más

28/02/2017

UNIVERSITY COLLEGE...

8M€

Presupuesto del proyecto: 8M€

Líder del proyecto

UNIVERSITY COLLEGE LONDON No se ha especificado una descripción o un objeto social para esta compañía.

Fecha límite participación Sin fecha límite de participación.

Ver 5 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2017-02-28 No tenemos la información de la convocatoria

0% 77% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

5 Participantes

UNIVERSITY COLLEGE LONDON

2.67M€ | Lider

UNIVERSITY COLLEGE LONDON

Health Proc Europe Associati...

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

GLIOMA Targeting Glioblastoma using Combinatorial Therapeutic Nanov... 195K€ Cerrado

EXPERT EXpanding Platforms for Efficacious mRNA Therapeutics 15M€ Cerrado

MAGNOSTICS Biomimetic MAGnetic nanoparticles with homotypic targeting f... 173K€ Cerrado

TherACCage Therapeutic Artificial Cells based on Molecular Cages for Gl... 181K€ Cerrado

THERAGEL Development of a chemotherapeutic gel for glioblastoma multi... 176K€ Cerrado

ANTICARB Monoclonal ANTIbody targeted CARBon nanobues against cancer 4M€ Cerrado

Líder del proyecto

UNIVERSITY COLLEGE LONDON No se ha especificado una descripción o un objeto social para esta compañía.

Presupuesto del proyecto 8M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto DARTRIX, ‘DARPin Targeted RX (therapy)’ is a multidisciplinary collaborative project that will develop high-affinity protein scaffolds to create a new generation of targeted therapeutics for the treatment of glioblastoma. There is great need; glioblastoma is virtually incurable and most patients die within 12 months of diagnosis. DARPins are small, non-immunoglobulin human protein scaffolds that bind specific targets with exceptionally high-affinity. DARPins are amenable to GMP production and to scale-up. They are remarkably stable, even at high temperatures and they can be engineered to incorporate additional favourable properties to target glioblastoma cells with exceptionally high affinity. The new DARPins will be coupled to dextran-coated iron oxide nanoparticles, such as ferucarbotran or nanomag-MIP, which has been used clinically as a contrast agent for Magnetic Resonance Imaging (MRI). These ‘particles’ are safe to use in patients and are traceable within the body. When stimulated by an appropriate alternating magnetic current, the particles generate heat that can kill cancer cells very effectively. The conjugation of DARPins with ferucarbotran or nanomag-MIP (DARTRIX particle) leads to a potent therapeutic by delivering targeted hyperthermia to glioblastoma. In addition, DARTRIX particle will be created economically, exploiting the fact that DARPins can be produced to GMP in gram quantities using E. coli. The DARTRIX particles will target to glioblastoma cells by virtue of the high affinity and specificity of DARPins and the particles will remain in place when heated. By using DARPins to target the DARTRIX particle to tumour cells before application of the magnetic current, it should be possible to generate toxic heat specifically in the tumour. The consortium has all the skills and knowledge to develop DARPins from bench-to-bedside for glioblastoma treatment. This DARTRIX particle will pioneer targeted hyperthermic cancer treatment of glioblastoma in an innovative adaptive first-in-man trial, using direct injection or convection enhanced delivery to localise the particles to the tumour.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores